NeoTX Therapeutics to Present at the Society for Immunotherapy of Cancer’s 34th Annual Meeting

REHOVOT, Israel, Nov. 04, 2019 (GLOBE NEWSWIRE) — NeoTX Therapeutics, Ltd. today announced a presentation on the company’s lead candidate from its Selective T cell Redirection (STR) platform, naptumomab estafenatox (Nap), at the Society for Immunotherapy of Cancer’s (SITC) 34th Annual Meeting being held November 6-10, 2019 in National Harbor, Maryland. The poster presentation will highlight preclinical data demonstrating that Nap and checkpoint inhibitors work synergistically to induce a prolonged and protective immune response against solid tumors. Details on the presentation are as follows: Abstract Title: Selective T cell Redirection Proteins (STR) Enhance the Anti-Tumor Activity of Checkpoint Inhibitors (CPIs) and can Lead to Long-Lasting Immunity Against the Tumor Abstract Number: P657 Presenter: Meir Azulay, Ph.D. Session Date & Time: Friday, November 8, 2019, 12:30 – 2:00 p.m. and 6:30 – 8:00 p.m. EST ← NeoTX Announces First Patient Dosed in Phase 1b Trial of Naptumomab Estafenatox (Nap) in Combination with Durvalumab in Solid Tumors → T Cell Redirection Drives Natural Immune Response Against Solid Tumors with Asher Nathan NeoTX (Empowered Patient Podcast) About Pipelines Technologies Clinical Trials News & Publications Careers Contact מחקרים קליניים טכנולוגיות ופרוייקטים חדשות © 2020 NeoTX, All Rights Reserved. Privacy Policy | Terms of Use About Pipelines Technologies ▼ NAP Clinical Trials News & Publications Careers Contact מחקרים קליניים טכנולוגיות ופרוייקטים חדשות

The release as fetched from its publisher. neotx.com ↗